Detalhe da pesquisa
1.
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Nature
; 618(7963): 144-150, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37165196
2.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
Oncologist
; 23(6): 654-e58, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29438092
3.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(4): 375-e30, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28275117
4.
Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.
Magn Reson Med
; 77(2): 814-825, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26918893
5.
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36918220
6.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(10): 1281, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29018169
7.
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene.
Cancer Cell
; 3(1): 89-95, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12559178
8.
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 28(16): 3452-3463, 2022 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35699599
9.
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Clin Cancer Res
; 25(11): 3220-3228, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770348
10.
De novo CpG island methylation in human cancer cells.
Cancer Res
; 66(2): 682-92, 2006 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16423997
11.
Phase I study of the anti-α5ß1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 82(2): 339-351, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29905898
12.
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
J Clin Oncol
; 36(9): 850-858, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29341833
13.
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.
Nature
; 416(6880): 552-6, 2002 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-11932749